Caribou Biosciences, Inc. CRBU
We are a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats ("CRISPR") genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Our genome-editing platform is based on our novel chRDNA (CRISPR hybrid RNA-DNA, or "chRDNA," pronounced "chardonnay") genome-editing technology, which enables more precise genome editing of allogeneic cell therapies.
Our allogeneic, or off-the-shelf, chimeric antigen receptor ("CAR") -T ("CAR-T") cell therapy product candidates are manufactured in advance with cells from healthy donors, with the goal of enabling broad patient access, rapid patient treatment, and increased manufacturing scale. Our allogeneic CAR-T cell therapy product candidates in clinical development are directed at CD19 and B cell maturation antigen ("BCMA"), established cell surface targets against which autologous CAR-T cell therapeutics have already demonstrated clinical proof of concept. We use our chRDNA technology to armor our cell therapy product candidates through genome-editing strategies, such as checkpoint disruption and immune cloaking, to enhance activity against hematologic malignancies.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.2M | $10.0M | $34.5M | $13.9M | $9.6M | $12.4M | $5.8M | — |
| R&D | $109.4M | $130.2M | $112.1M | $82.2M | $52.3M | $34.4M | $23.6M | — |
| SG&A | $37.9M | $46.5M | $38.5M | $38.0M | $24.3M | $14.1M | $16.5M | — |
| Total operating expenses | $159.5M | $176.6M | $150.5M | $120.2M | $76.6M | $48.5M | $40.1M | — |
| Operating income | -$148.3M | -$166.6M | -$116.1M | -$106.4M | -$67.0M | -$36.1M | -$34.3M | — |
| Interest expense | — | — | — | — | $8.0K | $20.0K | $4.0K | — |
| Pre-tax income | -$148.7M | -$149.1M | -$101.9M | -$99.4M | -$66.6M | -$36.1M | -$31.0M | — |
| Income tax | $550.0K | $9.0K | $193.0K | $70.0K | $321.0K | $1.8M | $7.5M | — |
| Net income | -$148.1M | -$149.1M | -$102.1M | -$99.4M | -$66.9M | -$34.3M | -$23.4M | — |
| EPS, basic | -1.59 | -1.65 | -1.38 | -1.64 | -2.11 | — | — | — |
| EPS, diluted | -1.59 | -1.65 | -1.38 | -1.64 | -2.11 | -4.01 | -2.80 | — |
| Shares, diluted (wtd. avg.) | $93.4M | $90.3M | $73.8M | $60.8M | $31.7M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $12.4M | $16.3M | $51.2M | $58.4M | $240.5M | $16.0M | $41.1M | — |
| Short-term investments | $127.0M | $193.2M | $277.7M | $189.3M | $135.4M | $0 | — | — |
| Receivables | $69.0K | $265.0K | $148.0K | $202.0K | $1.2M | $150.0K | — | — |
| Total current assets | $145.2M | $219.4M | $338.8M | $260.2M | $391.2M | $24.3M | — | — |
| Property, plant and equipment | $6.8M | $19.3M | $18.3M | $10.7M | $4.9M | $3.5M | — | — |
| Total assets | $175.4M | $313.3M | $432.2M | $373.8M | $442.4M | $36.0M | — | — |
| Accounts payable | $5.8M | $2.5M | $3.1M | $1.1M | $4.0M | $2.6M | — | — |
| Total current liabilities | $25.4M | $30.7M | $28.3M | $28.1M | $25.8M | $12.4M | — | — |
| Total liabilities | $53.2M | $60.4M | $63.8M | $72.9M | $54.5M | $18.2M | — | — |
| Retained earnings | -$596.5M | -$448.4M | -$299.3M | -$197.2M | -$97.8M | -$30.9M | — | — |
| Total equity | $122.2M | $253.0M | $368.4M | $300.9M | $387.8M | -$23.4M | $7.5M | $29.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$111.0M | -$138.2M | -$93.3M | -$91.0M | -$32.5M | -$33.2M | -$32.0M | — |
| Depreciation and amortisation | $3.6M | $3.9M | $3.5M | $1.6M | $984.0K | $900.0K | $751.0K | — |
| Stock-based compensation | $12.7M | $16.7M | $13.8M | $11.7M | $3.4M | $1.0M | $1.2M | — |
| Capital expenditure | $1.4M | $4.9M | $11.6M | $6.5M | $2.1M | $317.0K | $884.0K | — |
| Investing cash flow | $102.2M | $86.6M | -$68.2M | -$93.2M | -$176.4M | $6.4M | $27.2M | — |
| Financing cash flow | $4.8M | $16.7M | $154.3M | $2.1M | $433.4M | $1.7M | $172.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001619856-26-000008.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |